Skip to main content
OpenTrials
Completed

NCT Number: NCT00569244

SH T00186 in the Treatment of Primary Dysmenorrhea

The investigational drug SH T00186D is an oral contraceptive. The investigational drug used in this study contains the estrogen ethinylestradiol (EE) and the progestogen drospirenone (DRSP).

The aim of the present study is to evaluate efficacy and safety of the investigational drug in the treatment of menstrual pain (pelvic pain occurring shortly before, at onset, during menstruation). Two different regimens of intake of the same investigational product will be compared.

Patients have to undergo 2 -3 Baseline cycles (depending on whether the patient was an OC user before), during which menstrual pain, bleeding events, and pain killer intake have to be documented. During this observation period, the intake of hormonal contraceptives is not allowed. Other contraceptive methods (condoms with spermicide, pessary with spermicide) have to be used. If the patient is eligible for the study, she will be randomly assigned to one of the two treatment groups. Treatment group A will take the medication according to an extended flexible regimen, i.e., tablet intake will be triggered by bleeding events. Treatment group B will take the study medication in the 24 + 4 days regimen. That means, tablets to be taken on cycle days 1 - 24 contain the hormone combination, whereas tablets 25 - 28 do not contain any active ingredients, i.e., these are so called placebo tablets.

Treatment will last at least 140 days, but can be prolonged in Treatment Group A depending of occurrence of menstrual bleeding. The overall study duration will be 10 months for each patient.

During the whole study period, 5 visits are planned. At Screening and Final examination, a thorough physical examination and a gynecological examination (including breath palpation and cervical smear ) will be performed. Blood samples will be taken for safety laboratory parameters.

Additional examinations can be performed any time, if this becomes necessary for medical reasons.

Patients will be provided with a patient diary to document the intake of study medication, any bleeding events and days without bleeding, pregnancy test results, any dysmenorrheic (menstrual) pain and its intensity and its interference with daily activity, and intake of pain medication. The pain medication (ibuprofen) will be provided.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Dysmenorrhea Dysmenorrhea Menstruation Disturbances Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Pelvic Pain Signs and Symptoms

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Heidelberg, Baden-Wurttemberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Otherwise healthy female patients with moderate to severe primary dysmenorrhea
  • Prospective self-rated sum pain score of >/= 8 during the 2 baseline cycles
  • Age between 18 and 40 years (inclusive) with smoking habits as follows:
  • between 18 and 30 years of age. daily cigarette consumption not above 10
  • above 30 years of age, no smoking

Exclusion criteria

  • Current signs of history of any forms of secondary dysmenorrhea
  • Any concomitant disease of condition that requires any intake of analgesic medication
  • Occurrence of less than six menstrual cycles before Visit 1 following delivery, abortion, or lactation
  • Clinically significant depression

Treatment and study plan

Drug: YAZ flex (SH T00186D)

Drug

Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))

YAZ (SH T00186D)

Drug

YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))

Primary outcomes

  1. Number of days with dysmenorrheic pain

    Time frame: 140 days

Secondary outcomes

  1. Use of rescue medication

    Time frame: 140 days

  2. Interference with daily activity

    Time frame: 140 days

  3. Number of days: with at least moderate dysmenorrheic pain

    Time frame: 140 days

  4. Number of days with pelvic pain

    Time frame: 140 days

  5. Number of days with dysmenorrheic pain associated with withdrawal bleeding

    Time frame: 140 days

  6. Number of days with dysmenorrheic pain associated with unscheduled bleeding

    Time frame: 140 days

  7. Bleeding patterns

    Time frame: Whole treatment period

  8. Assessment of treatment

    Time frame: Whole treatment period

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

A Multi-center, Open-label, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-cyclodextrin Clathrate and 3 mg Drospirenone) Compared to the Conventional Regimen of SH T00186D in the Treatment of Primary Dysmenorrhea

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Dec 7, 2007
Registry last updated
Oct 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.